GoodRx co-CEOs out; former GoDaddy CEO to serve as interim chief executive
The leadership transition comes after a difficult few years for GoodRx, which announced in September that it planned to eliminate 16% of its workforce.
FDA approves new ALS medicine in precedent-setting decision
Biogen’s drug failed the key study meant to show it can slow the nerve-destroying disease, but the drug’s effect on a protein of interest led the FDA to conditionally clear it for market.
Humana boosts 2023 expectations for Medicare Advantage growth
The payer raised its guidance for earnings and revenue after beating Wall Street expectations on both metrics in the first quarter.
Tenet boosts full-year profit forecast after gains in Q1 volume growth
Surgical cases at the operator’s ambulatory unit climbed 8% year over year, leading to a surge in ambulatory operating revenue.
Centene lowers 2024 earnings guidance as Medicaid redeterminations roll out
The payer beat Wall Street expectations in the first quarter on both earnings and revenue, which reached $39 billion.
AHIP’s new ad spot targets pharma over drug costs as Congress scrutinizes PBMs
The ad spot comes as Congress heightens scrutiny of pharmacy benefit managers, drug purchasing middlemen that are often owned by health insurance companies.
LCMC ordered by judge not to close HCA-acquired hospitals as legal battle continues
The move comes as LCMC Health and the Federal Trade Commission file dueling court requests over whether state acquisition approval can preempt federal antitrust review of LCMC’s acquisition of three facilities from HCA Healthcare.
DOJ charges 18 in COVID healthcare frauds totaling $490M
So far, the Department of Justice has charged 53 defendants and convicted 20 in healthcare-related COVID-19 schemes.
HCA boosts 2023 full-year guidance on Q1 increase in net income, revenue
The operator logged an increase in admissions and a decrease in contract labor costs during the first quarter this year.
Supreme Court maintains access to abortion pill, blocking restrictions on its use
The stay suspends an order by a Texas judge that had invalidated the FDA’s approval of mifepristone, allowing access to continue while a circuit court hears the case.